NCT00081159View on ClinicalTrials.gov

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Metastatic CancerProstate Cancer
Interventions
DRUG

Doxorubicin hydrochloride

Doxorubicin 20 mg/m\^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.

DRUG

Goserelin acetate

DRUG

Leuprolide acetate

DRUG

Zoledronic acid

4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.

PROCEDURE

orchiectomy

RADIATION

strontium chloride Sr

1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment

Trial Locations (4)

54449

CCOP - Marshfield Clinic Research Foundation, Marshfield

32806-2134

M.D. Anderson Cancer Center at Orlando, Orlando

67214-3882

CCOP - Wichita, Wichita

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00081159 - Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases | Biotech Hunter | Biotech Hunter